Bristol Myers Squibb Jumps 6% on AstraZeneca Merger Talk — Is a $400 Billion Deal Even Sound?
Bristol Myers Squibb jumped 6% on reports of early-stage merger talks with AstraZeneca that could form a $400 billion pharma giant. AstraZeneca shares fell 7% on the same news — a split verdict that says as much about deal logic as deal size.